Drug intelligence / Profile preview

BVX004

Development stage: Preclinical
Lead developer: BiVictriX Therapeutics
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics

Overview

**BVX004** is a BiVictriX preclinical bispecific antibody-drug conjugate program for multiple solid tumors. Its two tumor-associated antigen targets and conjugated cytotoxic payload have not been publicly disclosed. BiVictriX listed the program as a discovery-stage solid-tumor bispecific ADC and reported in May 2025 that development had been paused to prioritize BVX002. ([bivictrix.com](https://bivictrix.com/science/?id=1))

Targets

CD7 (CD7 antigen)CD33 (Myeloid cell surface antigen CD33)

Beyond the preview

Go deeper on BVX004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BVX004.

Explore the full profile